Business Context and Reporting Period
This Form 8-K Current Report was filed by Processa Pharmaceuticals, Inc. on September 5, 2018. The filing reports the appointment of a new Chief Financial Officer and the execution of an employment agreement effective September 1, 2018.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change is the appointment of James Stanker as Chief Financial Officer. Mr. Stanker, age 60, previously provided financial consulting services to the Company and served as an audit partner with Grant Thornton LLP from 2000 to 2016.
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for the new CFO under the employment agreement:
- Base Salary: $87,500 annually.
- Stock Options: Grant of 334,400 options to purchase common stock at the closing price on the grant date.
- Vesting Schedule: 25% vests on September 1, 2019, with the remainder vesting monthly (1/48th) thereafter, contingent on continued employment.
- Acceleration Provisions: Options vest in full upon a Change in Control. If terminated without Cause or for Good Reason prior to September 1, 2019, 25% of options vest immediately.
- Severance: In the event of termination without Cause or for Good Reason in connection with a Change in Control, the executive receives six months of base salary.
The filing does not contain specific guidance, outlook, or management commentary regarding the Company's operational performance or future financial projections.
Investor Verification Checklist
- Verify the current cash position of Processa Pharmaceuticals to assess the ability to fund the new executive's salary and potential severance obligations.
- Review the dilution impact of the 334,400 stock options granted to the new CFO.
- Confirm the Company's current liquidity status given the lack of recent financial data in this specific filing.
- Examine the full Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change in Control."